Effects of a growth hormone receptor antagonist on bone markers in acromegaly.

What Was Tested

Researchers studied Receptors, Somatotropin in this randomized controlled trial publication.

IGF-I mediates many of the metabolic actions of GH, although GH may have direct effects upon bone.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and multicenter study.

The participants were allocated by chance, so the Receptors, Somatotropin group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Receptors, Somatotropin group a baseline to be compared against.

Running at several centres spread the Receptors, Somatotropin study over different clinics and patient groups.

Serum markers of bone turnover were determined at baseline and 12 weeks.

What Was Measured

The subject headings attached to it are Acromegaly, Biomarkers, Bone Density, Bone Remodeling, Collagen, Collagen Type I and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and multicenter study of Receptors, Somatotropin.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Clinical endocrinology), a journal based in England.

More context: all human trials.